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Background: Surgicel™ is an oxidized cellulose preparation that is widely applied in neurosurgery due to its
hemostatic effect and good tissue compatibility. Tumor-like lesions induced by Surgicel® application in cerebral
surgery have been rarely reported, especially for intracranial hemorrhage debridement surgery in patients with
hypertension.
Case presentation: This case report describes a rare case in which Surgicel™ application led to a foreign body
reaction, contributing to the development of an intracranial giant-cell granuloma. A 49-year-old female hypertensive
patient was diagnosed with intracranial hemorrhage. She was treated with debridement surgery that employed
Surgicel™ application. Although a satisfactory hemostatic effect was achieved, the patient was diagnosed with
epilepsy 6 months later. Subsequent magnetic resonance imaging revealed an intracranial space-occupying lesion.
After undergoing en bloc resection of the lesion, the patient was diagnosed with a Surgicel™-related intracranial
giant-cell granuloma by histopathology.
Conclusions: Application of Surgicel™ during intracranial hemorrhage debridement surgery may be associated with
a risk of granuloma development due to formation of a tumor-like space-occupying lesion in the surgery bed. Even
a low risk of tumor development implies a need for caution when applying Surgicel™, especially when solely used
to achieve a hemostatic effect.Background
In recent years, absorbable hemostatic materials have
emerged as standard tools in neurosurgery. Covering the
neurosurgical bed with hemostatic material helps to pre-
vent hematoma due to wound bleeding. As one of the
most widely applied absorbable hemostatic materials,
Surgicel™ (Ethicon, Inc., a Johnson & Johnson company;
Somerville, NJ) is an oxidized cellulose preparation ma-
nufactured by Ethicon Inc. of Johnson & Johnson Medical
Limited. Extensive clinical evidence has shown that the
application of Surgicel™ during cerebral surgery rapidly
promotes blood clotting and effectively controls bleeding.
Moreover, Surgicel™ has been demonstrated to display* Correspondence: jinluyu@hotmail.com
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reproduction in any medium, provided the orsuperior tissue compatibility compared to other resorbable
hemostatic agents [1-3].
A few cases of Surgicel™-induced foreign body reac-
tions have been reported, all of which involved organs
outside the nervous system; specifically, giant cell granu-
lomas developed in surgical beds of the cardiac, renal,
and adrenal gland tissues [4-6]. To the best of our know-
ledge, no previous report in the literature has described
Surgicel™-induced tumor-like lesions after hemorrhage
debridement surgery in hypertensive intracerebral he-
morrhage. Herein, we describe a case of giant-cell granu-
loma in the surgical bed following Surgicel™ application
in hemorrhage debridement surgery.
Case presentation
A 49-year-old female with a 5-year history of hyperten-
sion was hospitalized for grand mal seizures. Six months. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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with right basal ganglia hemorrhage via computed tom-
ography (CT) scan (Figure 1A) and underwent treatment
by hemorrhage debridement and craniotomy decom-
pression surgery. The surgical routine included the ap-
plication of Surgicel™ to stop bleeding in the surgical
bed. The postoperative recovery was unremarkable, and
the patient was discharged to resume independent living.
Two months after hemorrhage treatment, the patient re-
ceived a titanium plate to restore the skull structure.
Five months after hemorrhage treatment, the patient
suffered two grand mal seizures, which featured transi-
ent loss of consciousness and limb rigidity, with episodes
lasting approximately 5 minutes. Physical examination
upon hospital admission showed left upper limb muscle
strength of grade II, left lower limb muscle strength of
grade IV, and positive left Babinski sign, but no signs of
neurological defect.
Magnetic resonance imaging (MRI) studies showed an
irregularly shaped lesion in the right frontal temporal
lobe and basal ganglia, with a mixed signal (Figure 1B)
including reduced signals in T1WI and T2WI and anA
C
Figure 1 Images taken before and after surgery. (A) Computed tomogr
right basal ganglia. (B) Magnetic resonance imaging (MRI) results showing irre
ganglia, with mixed signal and dark fluid with low or higher signal. Lesion size
signal (arrow).increased signal indicative of dark fluid. After the signal
was strengthened, the MRI-detected lesion measured
1.7 cm × 3.7 cm (Figure 1C, 1D). Magnetic resonance
spectroscopy (MRS) studies showed a focal signal of
heterogeneous intensity, an unstable spectral baseline in
the lesion due to signal interference of liquid and hemo-
siderin, and an increased choline (Cho) peak and Cho/
N-acetylaspartate (NAA) ratio. The presence of abnor-
mal gliosis in the right frontotemporal lesion area led to
a diagnosis of suspected tumor (Figure 2).
The space-occupying lesion was surgically resected. The
titanium plate was removed, and the frontotemporal le-
sion and related dural adhesions were visually identified.
The gross appearance of the lesion included pale colo-
ration, rough surface, poor blood supply, and clear boun-
daries. The bottom of the lesion was tightly adhered to the
lateral ventricle. Under microscopic guidance, the lesion
was completely resected. The patient’s postoperative re-
covery was unremarkable. A CT scan 5 days after surgery
showed complete lesion exenteration.
Pathological analysis indicated a foreign body response,
as evidenced by substantial amounts of foam-like cellsD
B
aphy (CT) scan showing a region with high-intensity hemorrhage in the
gularly shaped lesions in the right frontal temporal lobe and basal
was 1.7 cm× 3.7 cm. (C-D) Lesion observed after strengthening the
AC D
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Figure 2 Magnetic resonance spectroscopy (MRS) analysis. (A) MRS showed a focally heterogeneous signal intensity and an unstable spectral
baseline in the lesion due to signal interference by the liquid and hemosiderin. (B) Increased choline (Cho) peak and CHO/N-acetylaspartate
(NAA) value were observed. (C-D) MRS of the left side was shown.
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led to the final diagnosis of a giant-cell granuloma caused
by Surgicel™ application (Figure 3). The patient was
discharged to home 8 days after surgery. There were no
remarkable physical, clinical, or imaging findings at the
6-month follow-up visit.
Discussion
The formation of surgical beds is unavoidable during
neurosurgery, and the normal soft structure of the brain
has insufficient strength to support the new vasculature.
Traditionally, hemostasis had been achieved during sur-
gery by electrical stimulation. However, this method can
cause some vessels to sink into the brain tissue, making
coagulation more difficult, or can liquefy the brain tissue,
causing irreparable injury [7]. The development of absorb-
able homeostatic materials to cover the surgery bed over-
came the risks associated with electrocoagulation, while
effectively achieving control of slight, especially oozing,
bleeding. The currently available absorbable homeostaticmaterials, including gelatin sponge, Surgicel™, and micro-
fiber collagen, are considered suitable for clinical applica-
tion due to their observed tissue compatibility.
Surgicel™ is an oxidized cellulose polymer, with poly-
glucuronic glucuronide as its effective functional unit.
Blood absorption initiates within 1 day after its applica-
tion, but complete absorption requires 4 to 8 weeks [8].
Compared to other hemostatic substances, Surgicel™ has
an especially high level of tissue compatibility; however,
occasional cases of foreign body reactions, such as ab-
scesses, inflammation, and giant-cell granuloma, have
been reported with its use [4-6,9,10]. Interestingly, in
each case of Surgicel™-induced giant-cell granuloma, the
granuloma was initially misdiagnosed as a tumor. For
example, Tefik et al. reported a case of Surgicel™-related
granuloma in a laparoscopic kidney tumor resection
surgery that was misdiagnosed as tumor recurrence
[9]. Gao et al. [10] reported a case of Surgicel™-related
granuloma that was misdiagnosed as a tumor 1 month
after hysterectomy and right oophorectomy. These
ACB
Figure 3 Histopathologic analysis of resected specimen. (A) Foreign body and giant cell reaction (left); gliosis (right) (magnification: ×200).
(B) Foreign body and foam-like cells assembled in the lesion tissue (magnification: ×400). (C) Gliosis observed in the lesion (magnification: ×400).
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side the nervous system were ultimately found to be due
to chronic inflammatory reactions. Overactivated giant
cells assembled around the Surgicel™, forming the
chronic giant-cell granuloma [11].
A similar immune-related mechanism may have con-
tributed, at least in part, to the Surgicel™-related granu-
loma observed in the brain of our patient. However, a
Surgicel™-related granuloma in the brain will have dis-
tinctive features from those involving other organs be-
cause the blood–brain barrier functions to prohibit giant
cell infiltration and assembly in the brain [12]. To ad-
dress this issue, we reviewed the clinical characteristics
of the previously reported Surgicel™-related granulomas,
and compared them to those of the granuloma in our
patient.
Sandhu et al. reported that the clinical manifestations
of two Surgicel™-related granulomas occurring after
brain tumor resection were similar to those of other
intracranial space-occupying lesions [13]. The time to
granuloma formation after Surgicel™ application in or-
gans outside the nervous system ranges from 1 to 36
months [10]. The two Surgicel™-related granulomas in
brain reported by Sandhu et al. formed within 1 and 3
months after surgery, respectively. In contrast, Ito et al.
reported three cases of Surgicel™-related granuloma for-
mation in brain that occurred within the time span of 13
to 21 months [14]. Hence, the few reported cases ofSurgicel™-related granuloma in brain appear to have
formed within the same timeline as Surgicel™-related
granulomas in other organs outside the nervous system.
Consistent with this finding, the Surgicel™-related granu-
loma case presented herein formed 6 months after sur-
gery for cerebral hemorrhage.
Another intriguing feature of Surgicel™-related granu-
lomas is the fact that they are commonly misdiagnosed
as brain tumors, particularly in cases of granuloma for-
ming after cerebral tumor resection. In two previous
cases, the Surgicel™-related granuloma manifested as a
space-occupying lesion with heterogeneous density by
CT scan [13,14] and mixed-signal with surrounding
edema by MRI [15]. Such imaging features do not facili-
tate the ability to distinguish a granuloma from a brain
tumor, increasing the risk of misdiagnosis. For our pa-
tient, MRS was used for further investigation of the
lesion and helped to identify the granuloma as a tumor.
To confirm the MRS-based tumor diagnosis, histopa-
thologic analysis of the resected lesion was performed.
Hematoxylin-eosin (HE) staining of the unabsorbed Surgi-
cel™ substance showed mild eosinophil infiltration (indi-
cated by blue or lavender coloration). Because the blood
clot around the unabsorbed Surgicel™ was gradually
absorbed, the Surgicel™ was left in place. The blood clot
appeared in the HE-stained lesion sections as a ‘ghostly’
fiber surrounding the Surgicel™ substance, and no tissue
accumulation was observed surrounding the Surgicel™.
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around these fibers [2]. The pathological hallmarks of this
case were consistent with the features of granuloma.
Hence, the case was diagnosed as Surgicel™-elicited granu-
loma. Although the features of Surgicel™-related granu-
loma are not distinguishable from those of tumor, this
case indicates that a tumor-like space-occupying lesion
that forms in the surgery bed after Surgicel™ application
during non-tumor surgery may have a high risk of beco-
ming a Surgicel™-related granuloma.
Conclusions
Although low, the risk of developing Surgicel™-related
granuloma after surgery indicates a need for caution in
applying Surgicel™, especially when it is used solely for
the purpose of achieving a hemostatic effect. However,
the risk of granuloma may be reduced by removing the
unabsorbed Surgicel™ after the hemostatic effect has
been achieved, or by reducing the amount of Surgicel™
applied. When a tumor-like space-occupying lesion is
observed in the intracranial surgery bed after surgery
employing Surgicel, the rare possibility of Surgicel™-
related granuloma should be considered.
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